Roche Pays Up to $2.3B for Muscle-Sparing Obesity Peptide

Roche's Genentech subsidiary has licensed HM17321, a peptide-based obesity candidate from South Korean pharmaceutical company Hanmi Pharm, in a deal worth up to $2.3 billion. Announced on 24 August 2026, the agreement covers worldwide rights to the compound outside South Korea. Beyond obesity, Hanmi said the candidate is intended for associated conditions such as type 2 diabetes and cardiovascular diseases.

A Non-Incretin Mechanism

HM17321 is a proprietary analogue of urocortin-2 (UCN2), a neuropeptide that binds to corticotropin-releasing factor type 2 (CRF2) receptors found in the central nervous system and in skeletal muscle. Hanmi describes the compound as a potential first-in-class treatment designed to promote weight loss while preserving lean body mass.

The mechanism sits outside the incretin pathway. Existing GLP-1 based therapies have demonstrated meaningful weight reduction, but they are associated with a reduction in lean body mass, an effect that has become a focal point of interest in obesity drug development.

Deal Terms

Hanmi will receive an upfront payment of USD 190 million. Including development, regulatory and commercial milestone payments, the total deal value could reach approximately USD 2.3 billion. Hanmi is also eligible for tiered royalties on future product sales.

Development Stage

Hanmi received investigational new drug (IND) clearance from the US FDA in November 2025. A Phase 1 clinical trial is ongoing, evaluating safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and individuals with obesity. Hanmi will complete Phase 1, after which Genentech takes over development beginning with Phase 2.

In preclinical studies, Hanmi reported both quantitative and qualitative improvements in weight reduction when HM17321 was used as a monotherapy and in combination with GLP-1 based therapies. The company says the peptide may have future potential in fixed-dose combination products or combination regimens with incretin-based treatments.

Research Context

The deal extends Roche's cardiometabolic pipeline, which includes the 2024 acquisition of Carmot Therapeutics and its dual-acting GLP-1/GIP agonist CT-388. UCN2 targeting is drawing wider interest. Danish peptide specialist Gubra began a Phase 1/2a clinical trial of its own lead UCN2 candidate, GUB-UNC2, in obesity last month.

Hanmi's senior vice president for R&D, In-Young Choi, said the paradigm of obesity treatment is evolving beyond simple weight reduction toward improving body composition and restoring metabolic health. Roche's head of corporate business development, Boris L. Zaïtra, said the company will pursue a differentiated approach to selectively reduce fat mass while improving muscle mass and function.

What to Watch

Phase 1 data from Hanmi's ongoing study will determine when Genentech assumes Phase 2 development. The agreement also signals sustained commercial interest in peptide mechanisms beyond the incretin class, particularly in body composition endpoints such as lean mass preservation.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.